Who is sponsoring NCT03699891?

NCT03699891 is sponsored by RTI Surgical.

What drugs are being tested in NCT03699891?

Interventions in NCT03699891: Fortilink IBF System with TETRAfuse Technology.

What condition does NCT03699891 study?

NCT03699891 studies Cervical and Lumbar Fusion.

Is NCT03699891 still recruiting?

NCT03699891 is currently completed. Last updated 2 October 2019.

Last reviewed 2019-10-02 · How we verify

NCT03699891: ENTRUST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Fortilink IBF System With TETRAfuse Technology

Completed Last updated 2 October 2019

What this trial tests

trial testing Fortilink IBF System with TETRAfuse Technology in Cervical and Lumbar Fusion in 119 participants. Completed in 15 January 2019.

Timeline

6 November 2018

Primary endpoint
15 January 2019

15 January 2019

Quick facts

Lead sponsor	RTI Surgical
Status	Completed
Study type	OBSERVATIONAL
Enrollment	119
Start date	6 November 2018
Primary completion	15 January 2019
Estimated completion	15 January 2019
Sites	5 locations across United States

Drugs / interventions tested

Fortilink IBF System with TETRAfuse Technology

Conditions studied

Cervical and Lumbar Fusion — all drugs for Cervical and Lumbar Fusion →

Sponsor

RTI Surgical

Who can join

Eligibility, any sex, with Cervical and Lumbar Fusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, post-market, retrospective study to collect safety and performance data for patients implanted with the Fortilink IBF System.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Fortilink IBF System with TETRAfuse Technology

Trials testing the same drug.

NCT03761563 — Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease · completed

Other RTI Surgical trials

Trials by the same sponsor.

NCT04171544 — Streamline Occipito-Cervico-Thoracic System Post-Market Clinical Follow-up · completed
NCT03744013 — A Post Market Prospective Study of FORTIVA® 1mm Porcine Dermis · NA · completed
NCT00975845 — BioCleanse Tibialis Tendon Anterior Cruciate Ligament (ACL) Study · completed
NCT02587403 — A Comparison of Fortiva and Strattice Tissue Matrices in Complex, Ventral Hernia Repair · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03699891 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RTI Surgical
Last refreshed: 2 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03699891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing